AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05234619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group one ( lidocaine or control LE ) Early deflation
Description: This will be conducted on 20 trauma patients group one who will be present for both elective and emergency Hand and Forearm surgery After establishing noninvasive arterial blood pressure, ECG, peripheral oxygen saturation monitoring, two venous cannulae will be inserted: one in a vein in the dorsum of operative hand and the other in the opposite hand for crystalloid infusion.~The opposite arm will be elevated for 2 minutes, and using an Esmarch bandage, the venous capacitance of the arm will be emptied. Then, a double-pneumatic tourniquet will be applied. The proximal tourniquet will be inflated to a pressure of 250 mmHg and circulatory isolation of the arm will be confirmed by inspection, lack of radial pulse and failure of pulse oximetry tracing of ipsilateral index finger then Esmarch bandage will be released then induction of lidocaine for intravenous regional anesthesia ( Bier block ) and Early deflation of distal tourniquet occurs after 20 minutes of IVRA induction
Study NCT05191498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuiremSpheres®
Description: Intratumoral injection of QuiremSpheres® up to a dose of 150 Gy.
Study NCT06126562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanifibranor
Description: Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist.
Study NCT06535581 — intervention group
Intervention type: PROCEDURE
Intervention: surgery patient
Description: patients with hypertension (group 2) and without (group 1) hypertension. The predictive ability of postoperative pain as a tool for measuring and assessing pain was examined by analysing the relative change in the Perfuston index.
Study NCT04800185 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Crisaborole 2% Top Oint
Description: To analyze the skin microbiome of patients with atopic dermatitis before, during, and after treatment with crisaborole 2% ointment
Study NCT04800185 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Skin Microbiome Swabs
Description: At the baseline visit the investigator will identify sites for swabbing the skin including one affected distinct crisaborole-treated AD lesion, and one untreated AD lesion. The lesions will both be sampled at baseline, 14 days into treatment, 28 days into treatment, 3 months into treatment, and 4 weeks after treatment completion. Photographs of each lesion will be taken for reference. Skin swabs will be obtained in a sterile fashion using a BD Culture SwabsTM EZ Collection and Transport System (or equivalent) and soaked with sterilized 0.15 M NaCl and 0.1% Tween-20. The samples will be frozen at -80 C, kept at this temperature, and stored until analysis may be completed.
Study NCT06416488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT intervention
Description: Modified HIIT in Tabata mode, which followed a pattern of 3 sets, with each set consisting of 4 repetitions of 20 seconds of high-intensity exercise followed by 10 seconds of rest, at least 3 times per week.
Study NCT06416488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health education
Description: General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
Study NCT06416488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General health education
Description: General instructions on promoting healthy diet and exercise, primarily by sending offline and online promotion materials to participants.
Study NCT04930029 — intervention group
Intervention type: OTHER
Intervention: Ten year evaluation
Description: Clinical, biological and endoscopic evaluation
Study NCT04888000 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Intervention
Description: Professional development program provided to small groups of health care professionals in three different sessions over a period of one month with additional independent individual work to be completed between sessions.
Study NCT06363916 — intervention group
Intervention type: DEVICE
Intervention: Insulin Management System in Manual mode of operation
Description: MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm not activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020
Study NCT05234619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group two ( lidocaine , ketorolac LKE ) Early deflation
Description: As the first intervention this will be conducted on group two but ketorolac will be combined with lidocaine in intravenous regional anesthesia
Study NCT05234619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group three ( lidocaine or control LL ) Late deflation
Description: As the first intervention this will be conducted on group three but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine for IVRA .
Study NCT06363916 — intervention group
Intervention type: DEVICE
Intervention: Insulin Management System in Automatic mode of operation
Description: MEDTRUM A8 TouchCare® Insulin Management system which includes:~* Patch pump: Pump base integrated with Hybrid Close Loop (HCL) algorithm activated~* Reservoir Patches~* Continuous glucose monitoring (CGM): Glucose Sensor + Transmitter~* Personal Diabetes Manager (PDM) and/or EasyPatch® App~* EasyFollow® App, EasyView® website System is in conformity with EC marking n° HD 601 357 110001- TUV Rheinland dated February 19th of year 2019 and completed by system DoC 881160 dated June 30th of year 2020.~EasyPatch mobile application is in conformity with EC marking n°709972 - BSI - dated March 6th 2020
Study NCT05002322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach
Description: Intensive phase: district MOH supervisors receive a one-week training on SAIA-HTN. The nine-month intervention wave will be mentored by INS study personnel who will accompany and support district MOH supervisors as they implement at the facility level. Over the first week of each iterative cycle, facility teams populate and interpret the HCAT, develop process maps, define one to two micro-interventions and indicators to monitor these modifications. Facility teams receive two mentorship visits by district supervisors and study personnel for the first month, followed by monthly visits throughout intensive implementation.~Sustainment phase (depending on implementation wave allocation): district supervisors will independently lead implementation, with financial support for travel to clinics and to hold meetings, but without intensive support from study personnel.
Study NCT05234619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group four ( lidocaine , ketorolac LKL ) Late deflation
Description: As the first intervention this will be conducted on group four but late deflation of distal tourniquet in intravenous regional anesthesia after 40 minutes of induction of lidocaine and ketorolac for IVRA .
Study NCT04528563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine 10 MG/ML
Description: Non-Steroidal-Anti-Inflammatory given intravenously.
Study NCT04528563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate 10Mg/1mL Injection
Description: Opioid commonly used for acute abdominal pain given intravenously.
Study NCT06356038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-operative phrenic nerve infiltration
Description: patients received the intra-operative infiltration of phrenic nerve by the surgeon who injected 10 ml of Ropivacaine 0.75% (the same procedure routinely adopted in our clinical practice for local analgesia at the level of the intercostal space) in the peri-neurotic pericardial fat, near the diaphragm. Infiltration is made with a deflated lung, after pulmonary resection and chest tube insertion.
Study NCT06573710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonic activator
Description: Polyamide EDDY tips 28mm long is inserted in the canal 2mm short of the working length operated at 6,000 Hz. Activation is done for three cycles each for 20sec. The tip is moved vertically in up and down motion, 1ml is used for each activation cycle followed by 2ml 17% EDTA20
Study NCT05061459 — intervention group
Intervention type: GENETIC
Intervention: circANKRD36 as a new biomarker
Description: expression levels of circANKRD36 in the development and progression of DN
Study NCT06573710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER activation
Description: Diode laser 980nm is used to activate the irrigant using fiber optic tip of (200micrometer) and power of 1.5w continuous mode. The tip is placed 2 mm shorter than the working length. Laser irradiation is done for each canal for 20 secs repeated over three cycles for total time of 60 secs and 10 secs pauses between each cycle
Study NCT06573710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic activation
Description: ED60tip is used with ultrasonic device operated on mode E and inserted in the canal 2mm short of the working. Activation is done for three cycles each for 20 sec. The tip is moved vertically in up and down motion,1ml is used for each activation cycle followed by 2ml 17% EDTA
Study NCT06573710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: passive irrigation with Endodontic needle
Description: Each canal is irrigated with side vented endodontic needle 30G Placed 2mm short of the working length with total time of 60 secs followed by 2ml 17% EDTA
Study NCT05791097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
Study NCT05791097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous infusion. 200 mg of tislelizumab will be administered on Day 1 of each 21-day cycle
Study NCT05354141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExoFlo
Description: Intravenous administration of bone marrow mesenchymal stem cell derived extracellular vesicles
Study NCT05896592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive electrophysiological study
Description: Invasive electrophysiological study consists in inserting two electrodes into the heart through femoral vein puncture into the right atrium and right ventricle. Then the following measurements are taken: SNRT- sinus rhythm recovery time, cSNRT- corrected sinus rhythm recovery time, Wenckebach point, AH and HV time and HRV-rhythm variability after SNRT measurement. The examination will be performed under general anesthesia.
Study NCT05896592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extracardiac vagal stimulation
Description: Extracardiac vagal stimulation consists in leading the electrode through the puncture of the femoral vein, successively to both internal jugular veins and stimulating the vagus nerve at the level of its cranial orifice and lower at the level of the angle of the mandible. Stimulation is performed using the Extra-Cardiac Autonomic NeuroStimulatorPachon.~Induction of a sinus pause or AV block during vagal stimulation is considered a positive test result. Absence of sinus pause and AV block during vagal stimulation indicates parasympathetic denervation of the heart. The examination is performed under general anesthesia.
Study NCT05896592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation
Description: CNA consists in complete parasympathetic denervation of the heart or in its deep neuromodulation by destroying the postganglionic nerve fibers of the vagus nerve, located in the epicardium in the vicinity of the pulmonary veins to the left atrium and in the area of the interatrial septum. It consists in inserting the electrode into the left atrium through puncture of the femoral vein, and then the interatrial septum, and performing ablation in the vicinity of the pulmonary vein orifices and on the interatrial septum at the level of the mitral annulus. Then the electrode is withdrawn into the right atrium and subsequent applications are made in the area of the coronary sinus opening and the roof of the right atrium and the upper part of the interatrial septum. The procedure is performed under general anesthesia. In group 1, CNA will be performed 1 month after randomization. In group 2, CNA will be performed 4 months after randomization.
Study NCT05896592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Redo cardioneuroablation
Description: It consists in re-performing the CNA if full parasympathetic parasympathetic denervation of the heart is not confirmed by ECVS.
Study NCT05896592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of the implantable loop recorder
Description: Implantation of the implantable loop recorder consists in subcutaneous implantation of the ECG loop recorder in the sternum area.
Study NCT05896592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pacemaker check
Description: It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Study NCT05896592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker check
Description: It consists in evaluating the reliability of the PM system. And the assessment of pacing percentage and recorded arrhythmias. After successful cardioneuroablation in groups 1 and 2, 4 months after randomization, the PM will be programmed to the VVI 30/min mode and after 6 months to the OAO/OVO mode. In group 3 patients and in the case of unsuccessful cardioneuroablation, the pacemaker will be set to the optimal mode for the patient. During the PM control, a non-invasive electrophysiological study (NIEPS) is also performed, in which the SNRT, cSNRT, Wenckebach point and HRV after SNRT measurement are assessed. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Study NCT05354141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline
Description: Placebo
Study NCT05896592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder check
Description: Assessment of arrhythmias recorded in the ILR. The procedure will be repeated at subsequent visits 3, 4, 6, 9, 12, 15, 18 months after randomization.
Study NCT05896592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Holter ECG
Description: 24 hour ECG recording. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Study NCT05896592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anamnesis
Description: Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Study NCT05896592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Anamnesis
Description: Medical history assessing symptoms of bradycardia, MAS, paraMAS and complications of performed procedures. The procedure will be repeated at subsequent visits 1, 3, 4, 6, 9, 12, 15, 18 months after randomization.
Study NCT04868877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
Study NCT04868877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Approved, 3rd-generation EGFR-TKI
Study NCT04868877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: administrated by IV infusion
Study NCT05671991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg vs Placebo
Description: Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
Study NCT05671991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Chronic Study- Empagliflozin 10 mg for 8 weeks
Study NCT06622824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 0.5% BID
Description: 0.5% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
Study NCT06622824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826 1.0% BID
Description: 1.0% of the investigational drug KX-826 to be applied topically to scalp twice daily for 24 weeks
Study NCT06622824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo) applied BID
Description: Matching placebo applied topically to scalp twice daily for 24 weeks
Study NCT06702215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-modal paired associative stimulation (cm-PAS) protocol
Description: The cross-modal Paired Associative Stimulation (cm-PAS) will consist of a visual stimulus depicting a hand being touched repeatedly paired with a transcranial magnetic stimulation (TMS) pulse delivered over the right primary somatosensory area, for a total of 150 paired stimuli delivered at a fixed frequency of 0.1 Hz. The time interval between the visual-touch onset and the TMS pulse will be 20 ms for the experimental session and 100 ms for the control session.
Study NCT06701877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circle of security Parenting (COS-P)
Description: The Circle of Security Parenting® (COS-P) program is an attachment-based intervention designed to enhance caregiver sensitivity, parental reflective functioning, and the quality of the child's attachment to their caregiver. This manualized intervention, with both educational and therapeutic components, empowers caregivers to better understand and respond to their child's needs, fostering secure attachment (22).
Study NCT06701877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traitement as usual (TAU)
Description: TAU typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families.
Study NCT06701877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traitement as usual (TAU)
Description: TAU typically involves home visits, educational and psychological support for foster carers and/or children in placement, and efforts to support and monitor contact between children and their birth families.
Study NCT04546126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Group 2)
Description: Participants will take 1 mg dexamethasone 2x a day for 3 days to suppress cortisol production.
Study NCT04546126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin (Group 3)
Description: Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
Study NCT04546126 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PET/CT Scan with FNP-59
Description: FNP-59, a radiotracer, is administered for PET/CT scans.
Study NCT06701240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentChild+
Description: 92-session early literacy focused intervention
Study NCT06701240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FamilyNutrition+
Description: 92-session active control focused on child nutrition
Study NCT06704139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine - .25 mg
Description: Fifty patients will receive intrathecal morphine
Study NCT06704139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl + morphine
Description: Fifty patients will receive intrathecal morphine and fentanyl
Study NCT06704139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Dexamethasone
Description: All patients will receive a compination of intravenous 4mg ondansteron and 8mg dexamethasone 15 minutes before spinal anathesia
Study NCT06702566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 and PD-L1 inhibitor
Description: PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.~PD-L1 inhibitor includes durvalumab,Atezolizumab,Adebrelimab,Envafolimab.
Study NCT06702566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted drugs
Description: Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
Study NCT06702566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Targeted drugs
Description: Targeted drugs includes EGFR-TKIs,ALK-TKIs,Multitargeted Tyrosine Kinase Inhibitors, VEGF antibody, EGFR antibody, antibody-drug conjugates drugs
Study NCT06702566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy drugs
Description: Chemotherapy drugs are determined based on the investigator's decision.
Study NCT06702566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy drugs
Description: Chemotherapy drugs are determined based on the investigator's decision.